Ruxolitinib for the Treatment of Acute Graft-Versus-Host Disease (aGVHD)


  • Utairat Meeudompong Pharmacy Department, Siriraj Hospital, Bangkok
  • Janjira Kaewla Pharmacy Department, Siriraj Hospital, Bangkok


Ruxolitinib aGVHD Steroid refractory


Ruxolitinib is a selective Janus Associated Kinase (JAK1 and JAK2) inhibitor indicated for graft-versus-host disease (GVHD). The drug works by dysregulating the JAK-STAT pathway, thereby reducing the incidence and severity of GVHD. It is the only FDA-approved drug for steroid-refractory acute GVHD in patients 12 years and older. The recommended dose is 5 mg orally twice daily, which can be increased to 10 mg twice daily after three days in the absence of toxicity. The overall response rate (ORR), defined as a partial or complete response to therapy, is 62%, and overall survival is 11.1 months. The most common adverse effects are thrombocytopenia, anemia, cytomegalovirus (CMV) infection, peripheral edema, neutropenia, hypokalemia and hypertension.


Download data is not yet available.


ทักษิณ จันทร์สิงห์.ความรู้ทั่วไปสำหรับเภสัชกรเกี่ยวกับการปลูกถ่ายเซลล์ต้นกำเนิดเม็ดเลือดในเด็ก.วารสารเภสัชกรรมไทย 2562.11:195-214.

National Comprehensive Cancer Network. Hematopoietic cell transplantation (HCT): Pre-transplant recipient evaluation and management of graft-versus-host disease 2020. Available form: Accessed May 16, 2020.

อาทิตย์ อังกานนท์. Graft versus host disease. วารสารโลหิตวิทยาและเวชศาสตร์บริการโลหิต2546.13:167-77.

Food and Drug Administration. FDA approves ruxolitinib for acute graft-versus-host disease2019.

Available form: May 16,2020.

JAKAFI® (ruxolitinib) [package insert]. Wilmington,DE: Incyte Corporation.;2019 Available from: https://www. Accessed May 20,2020.

Seif1 F, Khoshmirsafa M, Aazami H, Mohsenza degan M, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. J Cell Commun Signal 2017;15:23.

Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN,Chen YB, et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood 2020;135:1739-49.

Zeiser R, Bubnoff NV, Butler J, Niederwieser D, Or R, Szer J, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med 2020;382:1800-10.





Review Articles